(P20) Decreased PSA Nadir as a Result of Dose-Escalated Stereotactic Body Radiation for Patients With Low- and Intermediate-Risk Prostate Cancer

Prostate cancer (CaP) is characterized by a low a/b ratio relative to surrounding normal tissue, and consequently a therapeutic gain could be achieved with dose escalation. While potentially ablative PSA nadirs have been demonstrated following LDR brachytherapy, the ability to achieve ablation following stereotactic body radiation therapy (SBRT) remains unclear. The purpose of this study was to report the clinical outcomes, PSA kinetics, and toxicities in patients with low and intermediate-risk CaP treated on a prospective, Phase I/II, IRB approved dose-escalated SBRT trial.

https://ift.tt/2riL83z